Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded Fallopian tube cancer as a listed condition on the study page and updated the page revision to v3.4.2.SummaryDifference0.0%

- Check17 days agoChange DetectedMinor site maintenance: Revision: v3.4.1 added and Revision: v3.4.0 removed; no effect on study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedThis update adds a glossary toggle and updates certain metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted) and the revision to v3.4.0, with minor labeling adjustments for No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedLocations section expanded with numerous sites across US states and international regions, detailing where the trial is conducted.SummaryDifference2%

- Check89 days agoChange DetectedThe page shows a minor revision label update from v3.3.1 to v3.3.2. This change does not affect content or functionality of the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.